General Electric’s collapse should have served as a reminder that buying a company based solel...
Tekla: High Yield in Biotech
12/08/2014 7:00 am EST
Our strategy is to invest in areas that can’t help but burgeon over time; one such market is healthcare, which is booming, notes Mark Skousen, editor of Forecasts and Strategies.
One of my favorite closed-end biotech funds is Tekla Healthcare Investors (HQH), a Boston-based closed-end healthcare fund that primarily invests in biotechnology, medical devices, and pharmaceuticals.
It will also emphasize the smaller, emerging companies with a maximum of 40% of the fund’s assets in restricted securities of both public and private companies.
We recommended Tekla Heathcare several years ago when it was called H&Q Healthcare Investors and now we’re recommending it again. It has a great track record, having more than tripled since 2008.
Even so, it looks like a good deal. Tekla Healthcare is selling at only nine times earnings and it sports a rising dividend policy of more than 7% a year.
On October 1, it paid its most recent quarterly distribution of 56 cents per share, its seventh increase in a row.
The distribution consists of long-term and short-term capital gains. Currently, it is selling at a 2% premium to its net asset value of $31.25.
I suggest you add Tekla Healthcare Investors to your portfolio today and benefit from the biotech revolution and an above-average dividend and distribution.
More from MoneyShow.com:
Related Articles on STOCKS
What’s the concern? Debt. But not the national debt or even deficits, which are topics themsel...
The bulls are still long from both buy signals, signals are likely to fail. Most bulls will exit thi...
Macquarie Infrastructure Company (MIC) dropped over 40% after it reported fourth-quarter earnings on...